We read with interest the study by Mohanty et al1 assessing the effect of statins on the risk of decompensation and survival times in patients with hepatitis C-related compensated cirrhosis. The authors conducted a retrospective cohort study among 683 statin users and 2062 nonusers using data from the Veterans Affairs Clinical Case Registry. They found that statin use was associated with a dramatically reduced risk of decompensation (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.39-0.77) and death (HR, 0.56; 95% CI, 0.46-0.69) compared with nonuse.

We read with interest the study by Mohanty et al1 assessing the effect of statins on the risk of decompensation and survival times in patients with hepatitis C-related compensated cirrhosis. The authors conducted a retrospective cohort study among 683 statin users and 2062 nonusers using data from the Veterans Affairs Clinical Case Registry. They found that statin use was associated with a dramatically reduced risk of decompensation (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.39-0.77) and death (HR, 0.56; 95% CI, 0.46-0.69) compared with nonuse.